On the 24th, the Macao Coordination Center for Coordination of New Coronavirus Infections issued a notice indicating that the Macao Health Bureau has recently received a written notice from Fosun Industrial (Hong Kong) Co.
Tyco Biopharmaceuticals' mRNA COVID-19 vaccine (valid until June 2021) is related to packaging defects related to the cap of the vial.
Bain Tyco and Fosun Pharma have initiated investigations into the cause of the problem and must immediately suspend vaccination.
.
On the same day, the Hong Kong Special Administrative Region Government also issued the same press bulletin to suspend the announcement.
Screenshot of Macau SAR government announcement
Screenshot of the Hong Kong Special Administrative Region Government Announcement
According to previous reports in Hong Kong media, on February 27, 585,000 doses of the first batch of 1 million doses of Fupbitil vaccine were shipped from Germany to Hong Kong, and the remaining doses were shipped to Hong Kong in early March.
The 100,000 doses ordered by the Macau SAR government arrived in Macau via Hong Kong on February 28.
Therefore, with the issuance of the notice from the Macau Coordination Center for Coordination of New Coronavirus Infection, how Fosun Pharma will react has also attracted a lot of attention from the industry.
Renaissance emergency response to A+H shares double diving
Renaissance emergency response to A+H shares double diving
Not long after, Fosun Pharma responded to the news that "mRNA new crown vaccine is covered with related defects, Hong Kong and Macao will suspend vaccination today.
" The reply stated that for product safety considerations, BioNTech and the Group have initiated an investigation into the cause of the problem, and on March 24, 2021, the relevant authorities in Hong Kong and Macau have notified the relevant authorities in Hong Kong and Macau to suspend the vaccination batch number "210102" Of the vaccine until the end of the investigation.
In addition, out of prudence, the vaccine product with the batch number "210104" for supply to Hong Kong, China will also be sealed and will not be sent to all vaccination points until further notice.
Affected by this news, as of today's close, Fosun Pharma’s A shares fell 5.
78%, and Hong Kong shares fell 4.
83%.
It is understood that the mRNA new crown vaccine BNT162b2 mentioned in this announcement was first developed by Baintech, Germany.
On March 16, 2020, Fosun Pharma and the company reached a new crown vaccine research and development cooperation, and was authorized to operate in mainland China and Clinical trials, listing applications and commercialization in Hong Kong, Macau and Taiwan.
In January and February of this year, BNT162b2 was approved for emergency use in Hong Kong, China and a special import license from the Health Bureau of Macau, China.
As of the date of this announcement, the vaccine is still in Phase II clinical phase in Mainland China.
5 new crown vaccines have been listed in China
5 new crown vaccines have been listed in ChinaAccording to the previous press conference held by the State Council’s Joint Prevention and Control Mechanism on the safety and effectiveness of the new coronavirus vaccine, there are currently 5 vaccines in my country, namely:
Inactivated vaccine:
Sinopharm Zhongsheng Beijing Company's new coronavirus inactivated vaccine was approved for listing with conditions on December 31, 2020;
Kexing Zhongwei new coronavirus inactivated vaccine was approved for marketing with conditions on February 5, 2021;
Sinopharm Zhongsheng Wuhan Company's new coronavirus inactivated vaccine was approved for marketing conditionally on February 25, 2021.
Adenovirus vector vaccine:
The recombinant new coronavirus vaccine developed by CanSino Bio will be approved for marketing with conditions on February 25, 2021.
Recombinant protein vaccine:
The Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongke Co.
, Ltd.
jointly developed a recombinant new crown vaccine approved for emergency use on March 18, 2021.
Yesterday, CanSinoBio issued an announcement on the Hong Kong Stock Exchange stating that the inhaled recombinant new coronavirus vaccine (type 5 adenovirus vector) developed in cooperation with the Institute of Bioengineering, Academy of Military Sciences, Academy of Military Sciences of the Chinese People’s Liberation Army obtained NMPA on March 22 Approval for clinical trials of drugs.
Although there is no direct evidence in the announcement issued by Fosun at midday to indicate whether the safety of this batch of products is at risk, under such fierce competition in the domestic vaccine approval market, whether Fosun Pharma’s voluntary recall will give it a later stage Relevant product research and development will bring uncertainties in China's approval, which remains to be seen.
Reference: "Fosun Pharma: Vaccines are suspended from use in Hong Kong and Macau and sealed up, and are highly responsible for product safety"
Reference: "Fosun Pharma: Vaccines are suspended from use in Hong Kong and Macau and sealed up, and are highly responsible for product safety"
